https://www.selleckchem.com/pr....oducts/mizagliflozin
On MVA, factors associated with failure to receive HCV treatment included Black race, higher MELD, and advanced clinical stage (all p0.05). HCV treatment for HCC patients portends improved survival, regardless of clinical stage, HCC treatment, or facility type. Efforts must address barriers to HCV treatment. HCV treatment for HCC patients portends improved survival, regardless of clinical stage, HCC treatment, or facility type. Efforts must address barriers to HCV treatment. Following the publication of the COMPASS trial, the
Like
Comment
Share
